Zobrazeno 1 - 10
of 38
pro vyhledávání: '"M B, Atkins"'
Autor:
M B Atkins, S Jang
Publikováno v:
Clinical Pharmacology & Therapeutics. 95:24-31
The discovery of activating BRAF mutations in melanomas has led to the investigation of small molecular inhibitors targeting BRAF mutation and MEK, a downstream protein within the mitogen-activated protein kinase (MAPK) pathway. This article reviews
Publikováno v:
The Journal of Immunology. 152:3189-3198
The objectives of this study were to determine whether intensive immunotherapy with IL-2 results in detectable levels of circulating IL-1 and TNF antagonists and whether the levels achieved in vivo are sufficient to affect the generation of secondary
Publikováno v:
Blood. 83:113-118
The aim of this study was to investigate whether interleukin (IL)-6 induces the production of IL-1 and tumor necrosis factor (TNF) antagonists. Serial plasma samples were obtained from cancer patients participating in phase I and II trials of recombi
Publikováno v:
The Journal of Immunology. 151:3299-3307
The objective of this study was 1) to investigate the in vivo production of IL-8 in patients undergoing IL-2 immunotherapy and 2) to study the influence of IL-1Ra, soluble TNF receptor p75 (TNFsRp75), and a TNFsRp75-Fc fusion protein on IL-2-induced
Autor:
Timothy A. Riley, C. D. Garcia, M. C. Pirrung, M. B. Atkins, Michael Scurria, William B. Marvin, S. A. Hopkins, William J. Daily, David A. Schwartz, L. J. Jun. Arnold
Publikováno v:
ChemInform. 28
Publikováno v:
Proceedings of the National Academy of Sciences. 89:11598-11602
The export of leukotriene (LT) C4 from human eosinophils, a carrier-mediated process that is temperature-dependent and saturable, was characterized further in eosinophils and in two human leukemia cell lines that do not present an intact 5-lipoxygena
Autor:
C, Curiel-Lewandrowski, M B, Atkins
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 2(11)
Clinical and laboratory observations suggest that host immunological responses may occasionally influence the course of melanoma, stimulating the investigation of immunotherapy approaches in this disease. Areas of active investigation have included r
Publikováno v:
Cancer chemotherapy and biological response modifiers. 19
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(3)
CNI-1493, an inhibitor of proinflammatory cytokines, was studied in a Phase I trial in melanoma and renal cancer patients receiving high-dose interleukin 2 (IL-2). Objectives of the study were to define the maximum tolerated dose (MTD) and toxicity o
Autor:
D F, McDermott, J W, Mier, D P, Lawrence, M R, van den Brink, M A, Clancy, K M, Rubin, M B, Atkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(6)
In an effort to develop a biochemotherapy regimen for metastatic melanoma suitable for testing in a cooperative group setting, we modified the concurrent biochemotherapy regimen of S. S. Legha et al. (J. Clin. Oncol., 16: 1752-1759, 1998) by providin